Wakelee Shares Latest on Immunotherapy, EGFR Inhibitors in Lung Cancer – OncLive
OncLive |
Wakelee Shares Latest on Immunotherapy, EGFR Inhibitors in Lung Cancer
OncLive The scope of non–small cell lung cancer (NSCLC) has been progressively transforming every few months, with regulatory decisions and emerging regimens making their way through the pipeline, most recently with EGFR inhibitors and immunotherapy agents … |
